Company Overview
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +7.83% |
| 6 Months: | +11.71% |
| 3 Months: | -23.46% |
| 1 Month: | +3.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 37.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR Larimar Therapeutics, Inc. R2K | 3.72 | -1.75 | $386.44M | 0.00% | - | -109.83% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -13.24M | -17.61M | -19.72M | - | -17.86M | -15.06M | -14.83M | - | -13.27M | -13.54M | -12.84M | - | -15.70M | -15.56M | -15.17M | - | -13.28M | -3.70M | -8.63M | - | -6.67M | -11.40M | -10.34M | -12.11M | -12.54M | -16.73M | -8.89M | -8.69M | -8.51M | -7.64M | -9.62M | -10.34M | -16.73M | -24.60M | -18.26M | -31.19M | -27.79M | -49.50M | -31.12M |
| Net Income | - | -13.47M | -17.76M | -19.88M | - | -17.74M | -15.03M | -14.68M | - | -13.01M | -13.35M | -12.59M | - | -15.96M | -15.78M | -15.07M | -14.57M | -4.72M | -3.70M | -8.63M | -7.25M | -6.67M | -11.33M | -10.27M | -12.09M | -12.61M | -16.80M | -8.94M | -8.67M | -8.32M | -6.53M | -8.37M | -9.06M | -14.65M | -21.63M | -15.50M | -29.28M | -26.18M | -47.71M | -29.61M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.21 | -0.64 | -0.76 | -0.79 | -0.92 | -0.49 | -0.47 | -0.37 | -0.15 | -0.19 | -0.21 | -0.27 | -0.34 | -0.24 | -0.46 | -0.41 | -0.61 | - |
| R&D Expense | - | 10.21M | 12.53M | 14.17M | - | 12.50M | 10.16M | 10.00M | - | 9.68M | 10.53M | 9.72M | - | 12.43M | 12.21M | 11.83M | - | 9.63M | 3.13M | 8.03M | - | 5.01M | 8.91M | 6.92M | 8.97M | 9.10M | 14.03M | 5.81M | 5.64M | 5.58M | 4.56M | 5.88M | 6.58M | 12.94M | 19.68M | 13.92M | 26.55M | 23.37M | 44.93M | 25.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - |
| Operating Income | -13.79M | -13.78M | -35.53M | -73.81M | -58.23M | -53.00M | -61.12M | -23.21M | -42.80M | -50.47M | -36.53M | -41.76M | -90.89M | -172.50M |
| Net Income | -13.88M | -14.03M | -36.48M | -74.29M | -57.88M | -52.03M | -61.37M | -23.13M | -42.48M | -50.64M | -35.35M | -36.95M | -80.60M | -165.67M |
| Diluted EPS | - | - | - | - | - | - | - | - | -3.57 | -2.95 | -1.37 | -0.84 | -1.32 | - |
| R&D Expense | 11.54M | 9.56M | 27.39M | 54.62M | 39.94M | 40.84M | 47.93M | 20.79M | 31.41M | 38.40M | 24.25M | 27.67M | 73.28M | 154.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 38.14M | 117.52M | 189.11M | 131.62M | 105.51M | 121.76M | 5.20M | 104.69M | 78.67M | 126.41M | 95.94M | 200.22M | 145.84M |
| Total Equity | -40.92M | -54.73M | -68.57M | 104.44M | 169.11M | 121.73M | 78.22M | 2.91M | -694.00K | 89.69M | 64.41M | 110.90M | 81.72M | 171.81M | 78.08M |
| Cash & Equivalents | 1.47M | 9.94M | 35.52M | 58.10M | 35.59M | 32.35M | 40.78M | 49.33M | 1.01M | 68.15M | 70.10M | 26.82M | 26.75M | 33.22M | 85.41M |
| Long Term Debt | - | - | - | - | - | 3.18M | 20.00M | 20.00M | 14.54M | - | - | - | - | - | - |
| Total Liabilities | - | - | 2.92M | 13.08M | 20.00M | 9.89M | 27.29M | 28.49M | 5.89M | 14.99M | 14.25M | 15.50M | 14.21M | 28.41M | 67.76M |
| Current Liabilities | - | - | 2.92M | 6.90M | 16.54M | 9.89M | 7.29M | 13.31M | 5.89M | 8.99M | 8.85M | 10.71M | 9.51M | 24.36M | 64.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -51.98M | -43.78M | -51.49M | -22.70M | -42.20M | -42.10M | -27.57M | -33.46M | -70.76M | -113.20M |
| Investing Cash Flow | - | - | - | - | 51.45M | 35.65M | -6.87M | -83.00K | 17.09M | 24.17M | -90.96M | 33.35M | -85.39M | 100.31M |
| Financing Cash Flow | - | - | - | - | -2.71M | 16.56M | 66.91M | 19.39M | 93.59M | 19.89M | 75.26M | 30.00K | 161.88M | 65.09M |
| Capital Expenditure | -2.00K | -17.00K | -58.00K | -595.00K | -660.00K | -55.00K | -108.00K | -83.00K | -62.00K | -333.00K | -100.00K | -164.00K | -515.00K | -91.00K |
| Free Cash Flow | - | - | - | - | -52.63M | -43.84M | -51.59M | -22.78M | -42.26M | -42.44M | -27.67M | -33.62M | -71.28M | -113.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 25.4% | 20.5% | -34.9% | -43.9% | -47.5% | -66.5% | -2,106.0% | 3,333.1% | -47.4% | -78.6% | -31.9% | -45.2% | -46.9% | -212.2% |
| ROCE % | - | -39.1% | -32.1% | -42.8% | -47.8% | -54.0% | -56.4% | 3,345.0% | -44.7% | -72.3% | -31.6% | -48.3% | -51.7% | -212.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Deerfield Management Company, L.P | 34.28% | 35.61M | $119.28M |
| 2 | Blue Owl Capital Holdings LP | 6.85% | 7.12M | $23.85M |
| 3 | Blackrock Inc. | 3.61% | 3.75M | $12.57M |
| 4 | Millennium Management Llc | 3.49% | 3.63M | $12.14M |
| 5 | AIGH Capital Management LLC | 2.89% | 3.00M | $10.05M |
| 6 | Driehaus Capital Management, LLC | 2.82% | 2.93M | $9.83M |
| 7 | Vanguard Capital Management LLC | 2.76% | 2.87M | $9.60M |
| 8 | DAFNA Capital Management, LLC | 1.95% | 2.03M | $6.80M |
| 9 | Goldman Sachs Group Inc | 1.50% | 1.56M | $5.23M |
| 10 | RTW Investments LP | 1.44% | 1.50M | $5.02M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LRMR
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNSjgwQ2Nsc1pERVduanRpbWNhZVB2YWw3REEwZ2JyZ3lSbmRaRGFycHhtT00tem51Y0lRZk9mTW1DU1ZibDIwYzdwS3RUOTRPT3RnY09JY2VHeHFhUzVLVHNKQUNYWExXZUcxUW9LTVJOZmNkeWxHQ29wZHZXR1phVHZ1SWRkanJodG03UG…
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQQmU4N2hWTlEwb1lUSHJfeXlnOFlDbkRyWUNyZWxPT29QX3Z0NUl0eTE4UGJTZGEtM3U5dEhYeGNNRFVwMHROZm1CdzhVenJlRDA1OFNnTHozaThIWVZ1ejlsQzdLOUhHSXpiT2VCR1FDM2d0VDZLd0c3WjZRcDM0RGgwVGhkNWczem9Fb2…
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOVE1NX2UwNVZHdDBEajlQMmlMajJWVzNZa2lnZEZHQy13RTlGWUZJSEw0Q2xzcWY2YXN2WUlBZUVCU2c4ek5RalgyVGlCWG5UYWE0bFdPdVFDaE9nNF9lM09MUDZuWmM5MmdIVm5mOXVZd3JweHlNem1IcmhSa21MYnNXQlJDbERoajM0ZW…
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTFB4Y3hrbTkzODRfOWwyN1R0eTdRUF9KZUJkdUQtZHpDNHc2bVQwLWg1WGZ4QWR1R3lobWRyUDNGVGNucmpzYmgyMFdrNERnakpXTnVQTk1WRUtYajA?oc=5" target="_blank">LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ…
Larimar Therapeutics (LRMR) director purchases 50,000 common shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQUnpaamUyRFRDOGd0dVRLMUNMcUZSSmNGV3dyZHhvdlhJaGdyUEhXVTh6Nl8yN2RfeVR3UGhrTjdoMEhhMnJwcF9TQzhjTFR3YUFjdnl5TlVKQUpSQVBnbzBadkowdUdZbm5MX1FZUVVaYXhsa0ZlMGJab0lHSDBKNm5lZ0lQMy1OaldMUD…
Larimar Therapeutics stock jumps on insider purchase - Investing.com
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOV1hmYWltNXBDcEJXUUZsQUZOYmpQTnZkOU5kNWF5Y1hGUWZ3XzVQcnF5aXBiNURFT0ZsV2ZlUlNISVRxT0ZWQXJqa3UwOW1NcUV1SVR0LWV2dEVhTTZaMW1ESWtxODFjY1dYZGt1bzZ2VllmQ0g3ZFZ6cU1DejhMQk9lQzA0ejdkenNDUm…
LRMR — Frequently Asked Questions
What is the current share price of Larimar Therapeutics, Inc. (LRMR)?
As of 2026-07-14 21:23 PDT, Larimar Therapeutics, Inc. (LRMR) trades at $3.72 on NasdaqGM. Its 52-week range is $2.81 to $5.95.
What is the market capitalisation of LRMR?
Larimar Therapeutics, Inc. (LRMR) has a market capitalisation of $386.44M on NasdaqGM.
What is the P/E ratio of LRMR?
LRMR trades at a trailing price-to-earnings (P/E) ratio of -1.75. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.29.
What is the return on equity (ROE) of LRMR?
LRMR has a return on equity (ROE) of -109.83%.
Is LRMR a good stock to buy?
This page provides a data-driven analysis of Larimar Therapeutics, Inc. (LRMR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.